Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954

Cancer Gene Therapy

Volumn 7, Issue 5, 2000, Pages 721-731

  Djeha, A Hakim ^a,b,d   Hulme, Alison ^a   Dexter, Michael T ^b   Mountain, Andrew ^a   Young, Lawrence S ^c   Searle, Peter F ^c   Kerr, David J ^c   Wrighton, Christopher J ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Birmingham Office   (United Kingdom)

Author keywords

CB1954; Gene directed enzyme prodrug therapy; Hepatocellular carcinoma; Naked DNA; Nitroreductase; Squamous carcinoma

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; BACTERIAL ENZYME; DNA; NITROREDUCTASE; PRODRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CROSS LINKING; CYTOTOXICITY; ENZYME ACTIVITY; GENE THERAPY; HISTOLOGY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; XENOGRAFT;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA; ESCHERICHIA COLI; ESCHERICHIA COLI B; MAMMALIA;

EID: 0034109287     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700171     Document Type: Article

References (21)

1. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46: 5276-5281.
2. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 1993;43:380-387.
3. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 1992;89:33-37.
4. Connors TA. The choice of prodrugs for gene-directed enzyme prodrug therapy of cancer. Gene Ther. 1995;2:702-709.
5. Tubiana M, Malaise E. Growth rate and cells kinetics in human tumours: some prognostic and therapeutic implications. In: Symington T, Carter R, eds. Scientific Foundations of Oncology. London: Heinnemann; 1976:126-136.
6. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome p-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995;55:581-589.
7. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome p450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1995;1:1171-1177.
8. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome pp450/cyclophoshamide-based cancer gene therapy by coexpression of the p450 reductase gene. Cancer Res. 1997; 57:4830-4837.
9. Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 1996;56:4735-4742.
10. Knox RJ, Boland MP, Friedlos F, et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 1988; 37:4671-4677.
11. Bridgewater JA, Springer CJ, Knox RJ, et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer. 1995;31A:2362-2370.
12. Clark AJ, Iwobi M, Cui W, et al. Selective cell ablation in transgenic mice expressing E. coli nitroreductase. Gene Ther. 1997;4:101-110.
13. Drabek D, Guy J, Craig R, et al. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 1997; 4:93-100.
14. Green NK, Youngs DJ, Neoptolemos JP, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 1997;4:229-238.
15. McNeish IA, Green NK, Gilligan MG, et al. Virus-directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 1998;5:1061-1069.
16. Friedlos F, Court S, Ford M, et al. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. 1998;5:105-112.
17. Williams SG, Cranenburgh RM, Weiss AM, et al. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res. 1998;26:2120-124.
18. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer. 1995;31A:2335-2340.
19. Boland MP, Knox RJ, Roberts JJ. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB1954 (5-(aziridinyl-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol. 1991;41:867-875.
20. Bridgewater JA, Knox RJ, Pitts JD, et al. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther. 1997;8:709-717.
21. Vrionis FD, Wu JK, Qi P, et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther. 1997;4:577-585.